Multiple drug targets for the treatment of influenza identified using AI program

FHS
July 1, 2023
3:46 pm

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence (‘AI’) Programme with CytoReason.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In

November 14, 2024

Study offers the most comprehensive look to date on prostate cancer disparities

Cedars-Sinai Cancer investigators have found that Black men respond as well as white men to systemic therapies for advanced prostate cancer when access to quality

October 28, 2023

Study investigates senescent phenotypes of human corneal endothelial cells upon UV-A exposure

A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume

May 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.